Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Uk432097. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A known ✓ | P29274 | 20/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uk432097 SCHEMBL29379667 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1 | |
| Uk432097 SCHEMBL4369758 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL4369952 | 0.90 | ADORA2A (0.82) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL4369947 | 0.90 | ADORA2A (0.82) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL13863062 | 0.90 | ADORA2A (0.82) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL6304433 | 0.90 | ADORA2A (0.81) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL4375274 | 0.85 | ADORA2A (0.74) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL4375280 | 0.85 | ADORA2A (0.74) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL4383745 | 0.84 | ADORA2A (0.75) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL4383743 | 0.84 | ADORA2A (0.75) | ADORA2AADORA3ADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1292604-B1 | 2-AMINOCARBONYL-9H-PURINE DERIVATIVES | PFIZER LTD (GB) | 2009-05-13 | — | — | EP | claimed |
| US-7107985-B2 | Pharmaceutical combination | PFIZER, INC. (US) | 2006-09-19 | — | — | US | claimed |
| US-7094769-B2 | 2-aminocarbonyl-9H-purine derivatives | PFIZER INC (US) | 2006-08-22 | — | — | US | claimed |
| US-20060008421-A1 | Pharmaceutical combination | PFIZER INC | 2006-01-12 | — | — | US | claimed |
| US-6974803-B2 | Antiinflammatory agents; respiratory system disorders | PFIZER INC (US) | 2005-12-13 | — | — | US | claimed |
| US-20050250730-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-11-10 | — | — | US | claimed |
| US-20050209185-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-09-22 | — | — | US | claimed |
| EP-1455799-B1 | PHARMACEUTICAL COMBINATIONS OF ADENOSINE A-2A AND BETA-2-ADRENERGIC RECEPTOR AGONISTS | PFIZER LTD (GB) | 2005-04-27 | — | — | EP | claimed |
| US-20040171576-A1 | Adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases | PFIZER INC. | 2004-09-02 | — | — | US | claimed |
| US-6753322-B2 | 2-aminocarbonyl-9H-purine derivatives | PFIZER INC | 2004-06-22 | — | — | US | claimed |
| US-20030139369-A1 | Pharmaceutical combination | PFIZER INC. | 2003-07-24 | — | — | US | claimed |
| US-20030013675-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-01-16 | — | — | US | claimed |
| US-20210311050-A1 | TARGETING PATHOGENIC B CELLS IN AUTOIMMUNITY | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2021-10-07 | — | — | US | disclosed |
| US-10953015-B2 | Use of adenosine receptor signaling to regulate P-gp function | CORNELL UNIVERSITY (US) | 2021-03-23 | — | — | US | disclosed |
| WO-2020033624-A1 | TARGETING PATHOGENIC B CELLS IN AUTOIMMUNITY | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2020-02-13 | — | — | WO | disclosed |
| US-20190038630-A1 | USE OF ADENOSINE RECEPTOR SIGNALING TO REGULATE P-GP FUNCTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-02-07 | — | — | US | disclosed |
| WO-2003048180-A1 | CRYSTALLINE FORM OF A RIBOFURANOSYLURONAMIDE DERIVATIVE; A HUMAN ADENOSINE A2A RECEPTOR AGONIST | PFIZER LIMITED (GB) | 2003-06-12 | — | — | WO | disclosed |
| US-20030064034-A1 | Use of compounds in a dry powder inhaler | PFIZER INC. | 2003-04-03 | — | — | US | disclosed |
| US-20030013675-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-01-16 | — | — | US | disclosed |
| US-20020058641-A1 | 2-aminocarbonyl-9H-purine derivatives | PFIZER INC. | 2002-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209185-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA3 2/4885ADORA2B 3/4885 |
| US-20040171576-A1 | Adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA3 2/4885ADORA2B 4/4885 |
| US-20060008421-A1 | Pharmaceutical combination | ADRB2, ADRA2B, ADRA2C | ADORA2A 4/4885ADORA3 11/4885ADORA2B 5/4885 |
| US-20030013675-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA3 2/4885ADORA2B 3/4885 |
| US-20030139369-A1 | Pharmaceutical combination | ADRA2B, ADRB2, ADRA2A | ADORA2A 6/4885ADORA3 13/4885ADORA2B 5/4885 |
| US-20030064034-A1 | Use of compounds in a dry powder inhaler | QDPR, HRH4, HRH2 | ADORA2A 356/4885ADORA3 67/4885ADORA2B 179/4885 |
| US-20020058641-A1 | 2-aminocarbonyl-9H-purine derivatives | PNP, NUDT1, SLC29A1 | ADORA2A 9/4885ADORA3 21/4885ADORA2B 10/4885 |
| US-20210311050-A1 | TARGETING PATHOGENIC B CELLS IN AUTOIMMUNITY | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885ADORA3 3/4885ADORA2B 2/4885 |
| US-20050250730-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA3 2/4885ADORA2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.